 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
|
|
|
|
|
|
FDACounsel.com -- Legal Services -- for the life of a Life Sciences company
|
|
|
|
RESEARCH & DEVELOPMENT SERVICES -– The Pre-Approval Phases
|
|
|
|
Clinical Trial and Other Sourcing Agreements ♦ CROs • Sponsor Master Services Agreements • Clinical trials management ♦ Investigators ♦ Contract Labs • Preclinical testing ♦ IRBs ♦ Active Pharmaceutical Ingredient (API) supply sourcing ♦ Component sourcing deals ♦ Medical advisory boards • structure • function ♦ Consultants Commercial Agreements – FDA Issues Presented By: ♦ Co-Development Agreements (e.g., future marketing partners) ♦ Acquisitions involving pipeline products ♦ Clinical data ownership Good Clinical Practice (“GCP”) Compliance & Training ♦ SOPs – • drafting • review ♦ Compliance • audits • training ♦ HIPAA and privacy considerations • implementing procedures in clinical trials • consents ♦ State regulatory requirements Clinical Trial Protocol Reviews Informed Consent Reviews Financial Disclosure Requirements – Compliance and Strategies ♦ Federal: FDA & HHS ♦ Institutional (e.g., university, hospital) ♦ Clinical trial design to minimize conflicts
|
Investigational New Drug (IND) and Device (IDE) Submissions ♦ Pre-IND and IDE meetings • preparation • submissions ♦ INDs & IDEs • initial filing • maintenance during life of the IND – changes ♦ PDUFA, MDUFMA and Application Fees ♦ Device Reclassification Petitions – easing the regulatory burden • “De Novo” petitions for truly “new” technologies • Traditional for pre-’76 devices New Drug Applications (NDAs), Biologics License Applications (BLAs), Abbreviated NDAs (ANDAs), Device Pre-Market Approval (PMAs) Applications and Pre-Market Notification Submissions (510k’s) ♦ Counseling on requirements ♦ Strategies to maximize approval process ♦ Responding to FDA deficiency letters ♦ Achieving binding agreements with FDA on clinical design FDA Liaison & Meetings ♦ End-of-Phase meetings (I, II, III) ♦ Advisory Committee preparation and meetings Promotion and Advertising During R&D ♦ Reviews ♦ Training Emerging FDA Issues & Their Impact on Development Plans ♦ Comment preparation on FDA initiatives ♦ Legislative responses ♦ Client-generated strategic initiatives State Law Issues ♦ Privacy ♦ Medical Records
|
|
|
For "Life Cycle" Stages Legal Services, Just Click on The Related Button Below ...
|
|
|
|
|
|
|
|
|
|
|
For "Any Time" Legal Services, Just Click on The Related Button Below ...
|
|
|
|
|
|
|
|
|
|
|
For "Product/Topic Specific" Legal Services, Just Click on The Related Button Below ...
|
|
|
|
|
|
|
|
|
|
|
For presentations and articles on Drug & Device Development, just click here ...
|
|
|
|
For presentations and articles on Clinical Research, just click here ...
|
|
|
|
 |
|
|
|
© 2004 Law Offices of Michael A. Swit. ALL RIGHTS RESERVED.
Questions?
Contact us @ 760-815-4762 or mswit@fdacounsel.com
|
|